China Biologic Products Inc. (NASDAQ:CBPO)’s share price traded up 2.2% on Monday . The stock traded as high as $114.09 and last traded at $113.03, with a volume of 90,457 shares trading hands. The stock had previously closed at $110.64.

Several equities analysts have weighed in on the stock. Jefferies Group reiterated a “buy” rating on shares of China Biologic Products in a report on Saturday, June 4th. Credit Suisse Group AG upgraded shares of China Biologic Products from a “neutral” rating to an “outperform” rating in a report on Tuesday, July 5th. Finally, Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Thursday, May 19th.

The company has a 50-day moving average of $110.44 and a 200 day moving average of $115.62. The company has a market cap of $3.14 billion and a PE ratio of 35.35.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.06. The business had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $74 million. The business’s quarterly revenue was up 21.6% on a year-over-year basis. Equities research analysts anticipate that China Biologic Products Inc. will post $4.29 earnings per share for the current year.

In other news, CFO Ming Yang sold 13,908 shares of China Biologic Products stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $113.64, for a total transaction of $1,580,505.12. Following the completion of the sale, the chief financial officer now directly owns 52,282 shares in the company, valued at $5,941,326.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Ming Yin sold 19,618 shares of China Biologic Products stock in a transaction dated Friday, May 20th. The stock was sold at an average price of $113.64, for a total transaction of $2,229,389.52. Following the sale, the vice president now owns 51,419 shares of the company’s stock, valued at $5,843,255.16. The disclosure for this sale can be found here.

Other large investors have recently modified their holdings of the company. Russell Frank Co increased its stake in shares of China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock worth $1,993,000 after buying an additional 5,764 shares during the period. Employees Retirement System of Texas purchased a new stake in shares of China Biologic Products during the fourth quarter worth approximately $2,846,000. Finally, WCM Investment Management CA increased its stake in shares of China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock worth $8,655,000 after buying an additional 11,282 shares during the period.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.